Results 181 to 190 of about 10,268 (212)

Collagenous Colitis Associated With Lansoprazole

Journal of Clinical Gastroenterology, 2002
Collagenous colitis is a diarrheal illness of unknown cause. The purpose of this report is to describe a case of collagenous colitis related to lansoprazole exposure.Case report.A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole.
Gilbert M. Wilcox, Anthony Mattia
openaire   +3 more sources

Pharmacokinetics of Lansoprazole in Hemodialysis Patients

The Journal of Clinical Pharmacology, 1995
The pharmacokinetics of the new benzimidazole proton pump inhibitor lansoprazole and five of its metabolites were assessed after single oral dose administration to five hemodialysis patients. Patients were studied on dialysis and nondialysis days. Multiple blood and dialysate samples were collected after dosing and were assayed for lansoprazole and ...
John M. Cavanaugh, Joseph M. Machinist, Michael D. Karol   +2 more
openaire   +3 more sources

Safety of lansoprazole

Alimentary Pharmacology & Therapeutics, 1993
SUMMARYThe care with which patients are monitored during clinical trials provides an excellent database to assess the tolerability and safety of drugs. Additional information can be obtained from knowledge of the compound itself, its metabolism and its pharmacological action.
openaire   +4 more sources

Effect of Lansoprazole on Peptic Ulcers

Journal of Clinical Gastroenterology, 1995
Lansoprazole is the first proton pump inhibitor developed in Japan. We studied the clinical efficacy of lansoprazole 30 mg q.d. on peptic ulcers and the subsequent relapse rates. The endoscopic healing rate of gastric ulcers (n = 86) after 8 weeks of treatment and duodenal ulcers (n = 52) after 6 weeks of treatment were 94.2 and 96.2%, respectively ...
Tanenao Eto, Junichiro Sakata, Yasuaki Haraguchi, Tsuyoshi Ohashi   +3 more
openaire   +3 more sources

Diarrhea associated with lansoprazole

Journal of Gastroenterology and Hepatology, 2003
Abstract  Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease. According to the manufacturer's package insert (TAP Pharmaceuticals, Lake Forest, IL, USA), the most common side‐effects are diarrhea, headache and abdominal pain, which occur in approximately 3% of patients and are ...
openaire   +3 more sources

Lansoprazole, an antiulcerative drug

Acta Crystallographica Section C Crystal Structure Communications, 2000
Lansoprazole, 2-({[3-methyl-4-(2,2,2-trifluroethoxy)­pyri­din-2-yl]­methyl}­sulfinyl)-1H-benz­imidazole, C16H14F3N3O2S, is an antiulcerative agent. The mol­ecules in the lattice are held together by intermolecular hydrogen bonds between the NH group of benz­imidazole and the sulfinyl O atom.
G. Om Reddy, Krishnamurthi Vyas, A. Sivalakshmidevi   +2 more
openaire   +2 more sources

Lansoprazole: a cause of secretory diarrhea

The American Journal of Gastroenterology, 1998
A case of severe diarrhea and hypergastrinemia after 6 wk of lansoprazole therapy is presented. This represents the only fully evaluated report of severe diarrhea due to lansoprazole and comes to the interesting conclusion that it was a secretory diarrhea likely due to lansoprazole and not a gastrinoma or another cause.
openaire   +3 more sources

Pharmacokinetics and absolute bioavailability of lansoprazole

European Journal of Clinical Pharmacology, 1996
In a crossover study 12 healthy volunteers received lansoprazole 15 mg or 30 mg orally, or 15 mg intravenously in randomized order as a single dose. Blood samples were taken and plasma levels of lansoprazole were determined using an HPLC method. The volunteers were phenotyped for the debrisoquine/sparteine and mephenytoin polymorphisms.The total ...
J Gerloff, H Barth, A Mignot, K Heintze
openaire   +3 more sources

Lansoprazole: Alternate Day Dosing [PDF]

Hospital Pharmacy, 2003
Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses.
Joyce A. Generali, Dennis J. Cada
openaire   +1 more source

Pharmacokinetic Interaction Between Lansoprazole and Theophylline

Therapeutic Drug Monitoring, 1995
The pharmacokinetic interaction potential of the new proton-pump inhibitor lansoprazole and theophylline was assessed in a double-blind, two-period (13-day duration per period), multiple-dose crossover study in 14 healthy male volunteers. Lansoprazole 60 mg or placebo once daily was coadministered with anhydrous theophylline 200 mg four times daily ...
J H Cavanaugh, M D Karol, C S Locke, G R Granneman   +3 more
openaire   +2 more sources